Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis

García-Torralba, Esmeralda; Spada, Francesca; Lim, Kok Haw Jonathan; Jacobs, Timothy W.; Barriuso, Jorge; Mansoor, Was; McNamara, Mairéad G.; Manoharan, Prakash; Fazio, Nicola; Valle, Juan W.; Lamarca, Ángela

doi:10.1016/j.ctrv.2021.102168

Cited by 9 publications

(4 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cumulative survival curve of the entire sample, starting from the diagnosis of bone metastases, shows a 10-year survival of 33%. The average overall survival of our sample has been found to be about 80 months, which is higher than the data published before in the literature ( 10 , 16 ). A possible explanation for this could be that the implementation of MR and PET-TC with radiolabeled SSA allows to obtain at earlier stages the diagnosis, treatment and follow-up of the bone metastases.…”

Section: Discussioncontrasting

confidence: 72%

“…The analysis of our cases highlights a total prevalence of bone metastases of 20.5% (72 cases out of 351 patients). It appears to be higher than pooled incidence (18.4%) reported in a recent systematic review published by Garcia-Torralba et al ( 10 ). The growing prevalence of BM from NET through the years could reflect an increasing attention to this topic and a greater diagnostic accuracy related to the more extensive use of MRI and PET/CT with radiolabeled SSA.…”

Section: Discussioncontrasting

confidence: 58%

See 1 more Smart Citation

Bone metastases from neuroendocrine tumors: clinical and biological considerations

Scopel

Carlo

Bergamo

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

We considered 351 patients affected by neuroendocrine tumors, followed at the University Hospital of Padua and at the Veneto Oncological Institute. Of these, 72 (20.5%) suffered from bone metastases. The sample was divided according to the timing of presentation of bone metastases into synchronous (within 6 months of diagnosis of primary tumor) and metachronous (after 6 months). We collected data on the type and grading of the primary tumor, and on the features of bone metastases. Our analysis shows that the group of synchronous metastases generally presents primary tumors with a higher degree of malignancy rather than the ones of the metachronous group. This is supported by the finding of a Ki-67 level in GEP-NETs, at the diagnosis of bone metastases, significantly higher in the synchronous group. Moreover, in low-grade NETs, Chromogranin A values are higher in the patients with synchronous metastases, indicating a more burden of disease. The parameters of phospho-calcium metabolism are within the normal range, and we do not find significant differences between the groups. Serious bone complications are not frequent and are not correlated with the site of origin of the primary tumor. From the analysis of the survival curves of the total sample, a cumulative survival rate of 33% at 10 years emerges. The average survival is 80 months, higher than what reported in the literature, while the median is 84 months. In our observation period, synchronous patients tend to have a worse prognosis than metachronous ones with 52-months survival rates of 58% and 86%.

show abstract

Section: Discussioncontrasting

confidence: 72%

Section: Discussioncontrasting

confidence: 58%

Bone metastases from neuroendocrine tumors: clinical and biological considerations

Scopel

Carlo

Bergamo

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…A meta-analysis of 149 studies revealed an 18.4% incidence of bone metastases in NENs. Osteoclastic bone metastases were the most prevalent type, occurring metachronically (61.2%), with the axial skeleton being the primary site of metastasis [73]. In our study of 60 patients with neuroendocrine tumors, 5 patients had bone metastases.…”

Section: Discussionmentioning

confidence: 57%

Selected Parameters of Bone Turnover in Neuroendocrine Tumors—A Potential Clinical Use?

Strzelczyk

Wójcik-Giertuga

Strzelczyk

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Currently, there are no effective markers to diagnose and monitor patients with neuroendocrine tumors (NETs). The aim of this study was to assess bone metabolism based on selected markers of bone turnover: OST, OPG, and IGFBP-3, in both the group of patients with NETs and the control group. Associations with selected sociodemographic, biochemical, and clinicopathological characteristics were examined. We also evaluated any potential associations between these markers and selected biochemical markers of NETs commonly used in clinical practice. Methods: The study group included 60 patients with GEP-NETs and BP-NETs, while the control group comprised 62 healthy individuals. The serum concentrations of OST, OPG and IGFBP-3 were assessed using ELISA. Results: OST and OPG levels were significantly higher in the study group compared to the control group. In the study group, we observed a significant correlation between OPG and the clinical stage and chromogranin A. Additionally, an association was found between OPG and histological grade, Ki-67, and metastasis in GEP-NET cases. Conclusions: Markers of bone turnover cannot be used in the routine diagnostics of neuroendocrine tumors. Nonetheless, these markers may help evaluate the skeletal system in patients with NETs. Further research is needed to determine the utility of osteocalcin (OST) and osteoprotegerin (OPG) as potential biomarkers for neuroendocrine tumors.

show abstract

“…The most common symptoms of bone metastases are pain, pathological fractures, and metastatic spinal cord compression. They can lead to malignant hypercalcemia and worsened quality of life [7].…”

Section: Introductionmentioning

confidence: 99%

Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms

Rosiek

Janas

Witkowska

et al. 2023

JCM

View full text Add to dashboard Cite

We investigated the diagnostic capacity of selected circulating biomarkers (CBMs) for the early detection of bone metastasis (BMets) in patients with pancreatic neuroendocrine neoplasms (PanNENs). A total of 115 patients with PanNENs and 40 controls were enrolled. We measured the serum levels of ferritin, cytokeratin 18 (CY18), CA19-9, CA125, AFP, CEA, and beta-2 microglobulin (B2M). A total of eight PanNEN patients developed BMets, and one hundred seven remained BMets-free. We observed a significantly higher level of CA125 and CY18 in BMets patients vs. non-BMets patients (p = 0.01 and p = 0.04, respectively). CA125, CY18, and B2M area under receiver operator characteristic (AUROC) analyses differentiated both patients groups; CA125 area under the curve (AUC) 0.77, p < 0.01; CY18 AUC data were 0.72, p = 0.03, and B2M AUC 0.67, p = 0.02. On the basis of CBM metrics in both subgroups, we reached a sensitivity/specificity for CA125 of 75/76%; for CY18 of 75/69%, for B2M of 100/50%, for CA125, and the CY18 combination of 93/90%, respectively. According to current results, CA125 and CY18 seem to have the potential capacity as fair biomarkers for BMets detection, despite the small number of cases. Further studies are warranted in the larger PanNEN patient group.

show abstract

Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis

Cited by 9 publications

References 127 publications

Bone metastases from neuroendocrine tumors: clinical and biological considerations

Bone metastases from neuroendocrine tumors: clinical and biological considerations

Selected Parameters of Bone Turnover in Neuroendocrine Tumors—A Potential Clinical Use?

Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms

Contact Info

Product

Resources

About